Search results
Results from the WOW.Com Content Network
(Reuters) -Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
(Reuters) -Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting the main goal of ...
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...
Amgen shares closed at $287.87 on Wednesday, down about 9% from earlier this month, when analysts at Cantor Fitzgerald said their review of Phase 1 MariTide data showed a drop in bone mineral ...
AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]
In June 2013, Amgen Inc offered to buy the shares of Onyx Pharmaceuticals for $120 per share, sending the shares up by around 30% after the news was announced. [18] Onyx announced on June 30, 2013, that it rejected the unsolicited proposal from Amgen. The Onyx board has authorized its financial adviser to contact potential suitors. [19]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.